Overview
PMN market data
Price History
No market bars yet for PMN. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for PMN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026Globenewswire Inc · Jul 14, 2026, 11:00 AM
ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected SoonBenzinga · Jul 14, 2026, 7:22 AM
Cantor Fitzgerald Initiates Coverage On ProMIS Neurosciences with Overweight RatingBenzinga · Jun 30, 2026, 1:35 PM
HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price TargetBenzinga · Jun 24, 2026, 11:01 AM
8-K filing — ProMIS Neurosciences Inc. (PMN)SEC EDGAR · May 20, 2026, 8:30 PM